ClinicalTrials.gg
TerminatedNCT00978341Updated Jan 25, 2021Results posted

Study to Determine if a Reduction in Pain Can be Measured in Spinal Cord Injured Patients Using a New Study Design

An interventional study of Pregabalin and Placebo for pregabalin in Spinal Cord Injuries, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc.. Terminated at 4 sites in Australia. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2021-01-25.

Sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (part of Viatris Inc.) · Not applicable, Interventional, and Other

Why this study was terminated
See Detailed Description

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
15
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 17 studies in Spinal Cord Injuries with a site in Australia — 3 open to participants now, 3 under way, none of them phase 3. Spinal Cord Injuries · Australia.

Enrollment
11th of 15
15 · median 60
Started
2007
the only one that year
No phase
5 of 17
2 open now
Registered
3rd of 17
by date
Lead sponsor
1 of 17
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Among the 17 studies in Spinal Cord Injuries with a site in Australia, this one is the 11th largest by enrollment of the 15 interventional ones that give a count, is the only one that started in 2007, is one of 5 with no phase, and was the 3rd registered.

Spinal Cord Injuries

2,028 studies on the registry are indexed under Spinal Cord Injuries; 539 are open to participants now.

Browse Spinal Cord Injuries studies →

Open to participants now

3 of the 17 studies in Spinal Cord Injuries with a site in Australia are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →

Who these studies take

Of the 375 Spinal Cord Injuries studies recruiting now, 167 (45%) set no upper age limit and 157 (42%) stop at 75 or younger; 41 take children under 18; 52 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies in Spinal Cord Injuries with a site in Australia, or all of them as a file.
02

Study summary

The study is designed to assess if spinal cord injury patients have reduced pain after taking either pregabalin or placebo in a cross over design. Patients had either pain at the level of their injury or below the level of their injury.

Read the detailed description

This methodology study was terminated on October 13, 2008 based on interim results for an exploratory, novel endpoint. The results of the primary analysis at the interim for N=12 patients showed results that generally favored pregabalin but were not statistically significant compared to placebo. Based on the estimated conditional power, this result is unlikely to change with full recruitment of N=24 patients and therefore the data monitoring committee recommended termination of the trial. The decision to terminate the trial was not based on any safety concerns.

03

Conditions studied

  • Spinal Cord Injuries

Keywords

  • Clinical Trial Methodology study Neuropathic pain in Spinal cord injury patients Pain endpoints Crossover design
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • subjects who are outpatients or inpatients
  • written obtained (signed by the subject or the subject's legally acceptable representative)
  • traumatic spinal cord injury of at least 1 year duration with a nonprogressive, i.e., chronic, stage of at least 6 months duration
  • At-level neuropathic pain: spontaneous or evoked pain with neuropathic features (sharp, shooting, electric or burning pain sensation) in the region of sensory disturbance in a segmental pattern and located within two dermatomes above or below the level of spinal cord injury
  • Below-level neuropathic pain: spontaneous or evoked pain with neuropathic features (sharp, shooting, electric or burning pain sensation) in the region of sensory disturbance located at least three dermatomes below the level of spinal cord injury

Exclusion criteria

Exclusion Criteria:

  • spinal cord injury (subjects with central pain and musculoskeletal pain must be able to make a distinction between the two)
  • subjects who have previously not responded to 300 mg/day pregabalin: a non-responder is defined as a subject who has a reduction in pain score of less than 30% from baseline
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
15 participants (actual)

Study arms

  • Experimental
    Pregabalin

    Drug: Pregabalin

  • Other
    Placebo

    Drug: Placebo for pregabalin

Interventions

  • Pregabalin 150mg capsules BID for 7.5 days

  • DrugPlacebo for pregabalin

    Placebo capsules BID for 7.5 days

06

What researchers measure

Primary outcomes

  1. Present Pain Intensity Score

    Present pain intensity score: 0-10 numeric rating scale (NRS), 0 (no pain) to 10 (worst possible pain).

    Time frame: Day 1: 0 (pre-dose), 0.5, 1, 2, 3, 4, 5, 6, 8, 10, and 12 hours (post-dose); Day 8: 0 (pre-dose), 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 24, 36, and 48 hours (post-dose)

Secondary outcomes

  1. Daily Pain Score

    Daily Pain Score: Day 1 pain intensity over past 24 hours recorded on waking every morning. 0-10 numeric rating scale (NRS): 0 (no pain) to 10 (worst possible pain).

    Time frame: Predose: Daily from 7 days before Visit 2 (start of Intervention 1) until the morning of Visit 5 (end of Intervention 2)

  2. Dynamic Allodynia Area

    Area of dynamic allodynia was assessed using a brush (SENSElab Brush 05; velocity approximately 20 millimeters per second \[mm/s\]) by stimulating along a pattern of 8 radial spokes. Stimulation was started from the non-painful perimetry. Subjects were asked to report change in sensation from non-painful to painful and the spot was marked onto the skin. The area of dynamic allodynia was determined from these 8 distances by calculating the area of an octagon (in centimeter squared \[cm2\]).

    Time frame: Screening, Days 1 & 8: 0 (pre-dose) & 4 hours post-dose,

  3. Dynamic Allodynia Pain Score

    Five strokes (each approx. 6 centimeters \[cm\] long) were applied with a standardized brush (SENSELab Brush 05) across the painful site (and a control site) at a constant velocity (20 millimeters per second \[mm/sec\]). Pain in response to brush stimulation of the allodynic area was recorded using an 11-point numeric rating scale from 0 (no pain) to 10 (worst possible pain). Patients were asked to give a pain rating after each brush stroke. A painful sensation was considered as representing brush allodynia.

    Time frame: Screening, Days 1 & 8: 0 (pre-dose), 0.5, 1, 2, 3, 4, 5, and 6 hours post-dose

  4. Punctate Allodynia Area

    Area of punctate allodynia was determined using a von Frey filament (OptiHair2). Stimulation was started from the non-painful perimetry and repeated along a pattern of 8 radial spokes. With a movement along each spoke at steps of 5 millimeters (mm), the subjects reported sensation changes from non-painful to painful and the spot was marked on the skin. The area of punctate allodynia was determined from these 8 distances by calculating the area of an octagon (in square centimeter(s)\[cm2\]).

    Time frame: Screening, Days 1 & 8: 0 (pre-dose) and 4 hours post-dose

  5. Mechanical Pain Sensitivity Stimulus-Response Function

    Mechanical pain sensitivity stimulus response function was assessed at the control and painful sites using calibrated von Frey monofilaments and the SENSElab brush. Seven different von Frey monofilaments (8 -512 milliNewtons \[mN\], force increases by a factor of two from filament to filament) and the brush were applied in a predetermined pseudo-random order. Pain rating for each stimulus: 11-point numeric rating scale (NRS) ranging from 0 (no pain) to 10 (worst possible pain).

    Time frame: Screening, Days 1 & 8: 0 (pre-dose), & 2, 4, and 6 hours post-dose

  6. Neuropathic Pain Symptom Inventory (NPSI)

    NPSI: subject rated questionnaire to evaluate 5 dimensions of neuropathic pain (dimensions: burning \[superficial\] spontaneous pain, pressing \[deep\] spontaneous pain, paroxysmal pain, evoked pain, and paresthesia/dyesthesia). Includes 10 descriptors ranging from 0 (no symptoms) to 10 (worst symptoms imaginable) and 2 temporal items assessing duration of spontaneous ongoing and paroxysmal pain. Questionnaire generates a score in each relevant dimension. Total score is calculated as the sum of scores of the 10 descriptors, range: 0-100. Higher score indicates greater intensity of pain.

    Time frame: Prior to morning dosing on Day 1 and prior to discharge on Day 8 for each period.

  7. Pharmacokinetic Evaluations of Pregabalin

    Pharmacokinetic (PK) results are not presented in this report due to early termination of the trial. Pregabalin PK was not measured as there was incomplete data to conduct pharmacokinetic/pharmacodynamic analyses.

    Time frame: Day 1: 0 (pre-dose), 0.5, 1, 2, and 6 hours post-dose; Day 8: 0 (pre-dose), 1, 4, & 6 hours post-dose

07

Results

Posted Nov 9, 2009
Limitations and caveats
This study was terminated prematurely.

Participant flow

Subjects were enrolled at 4 study centers and participated in the study between 13 February 2007 and 01 October 2008.

First Intervention
Participant flow — First Intervention
MilestonePregabalin First Then PlaceboPlacebo First Then Pregabalin
Started87
Completed87
Not completed00
Washout Period of 2 Weeks
Participant flow — Washout Period of 2 Weeks
MilestonePregabalin First Then PlaceboPlacebo First Then Pregabalin
Started87
Completed77
Not completed10
Withdrew: Adverse event10
Second Intervention
Participant flow — Second Intervention
MilestonePregabalin First Then PlaceboPlacebo First Then Pregabalin
Started77
Completed77
Not completed00

Outcome measures

PrimaryPresent Pain Intensity Score

Present pain intensity score: 0-10 numeric rating scale (NRS), 0 (no pain) to 10 (worst possible pain).

Time frame:
Day 1: 0 (pre-dose), 0.5, 1, 2, 3, 4, 5, 6, 8, 10, and 12 hours (post-dose); Day 8: 0 (pre-dose), 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 24, 36, and 48 hours (post-dose)
Reported as:
Mean · scores on scale
Present Pain Intensity Score
scores on scalePregabalinPlacebo
Day 1: pre-dose (n=15, 14)5.3 ± 2.764.9 ± 2.91
Day 1: 0.5 hours post-dose (n=15, 14)5.1 ± 2.464.6 ± 3.03
Day 1: 1 hours post-dose (n=15, 14)4.6 ± 2.824.7 ± 2.55
Day 1: 2 hours post-dose (n=15, 14)4.3 ± 2.644.7 ± 2.64
Day 1: 3 hours post-dose (n=15, 14)4.3 ± 2.824.7 ± 2.73
Day 1: 4 hours post-dose (n=15, 14)4.1 ± 2.794.6 ± 2.98
Day 1: 5 hours post-dose (n=15, 14)3.9 ± 3.014.9 ± 3.02
Day 1: 6 hours post-dose (n=15, 14)3.9 ± 2.895.1 ± 2.91
Day 1: 8 hours post-dose (n=15, 14)4.3 ± 2.915.1 ± 2.57
Day 1: 10 hours post-dose (n=14, 14)4.1 ± 3.035.3 ± 2.81
Day 1: 12 hours post-dose (n=14, 14)4.1 ± 3.175.4 ± 2.68
Day 8: pre-dose (n=13, 14)4.7 ± 2.535.4 ± 2.62
Day 8: 0.5 hours post-dose (n=13, 14)4.5 ± 2.335.0 ± 2.57
Day 8: 1 hour post-dose (n=13, 14)4.0 ± 2.714.9 ± 2.60
Day 8: 2 hours post-dose (n=13, 14)4.6 ± 2.504.6 ± 2.38
Day 8: 3 hours post-dose (n=15, 14)4.9 ± 2.224.7 ± 2.52
Day 8: 4 hours post-dose (n=15, 14)4.9 ± 2.284.9 ± 2.53
Day 8: 5 hours post-dose (n=15, 14)4.8 ± 2.404.9 ± 2.63
Day 8: 6 hours post-dose (n=15, 14)4.4 ± 2.385.2 ± 2.72
Day 8: 8 hours post-dose (n=15, 13)4.7 ± 2.635.3 ± 2.90
Day 8: 10 hours post-dose (n=15, 13)4.9 ± 2.375.2 ± 2.85
Day 8: 12 hours post-dose (n=15, 13)4.7 ± 2.165.2 ± 2.65
Day 8: 24 hours post-dose (n=15, 14)5.0 ± 2.365.4 ± 2.71
Day 8: 36 hours post-dose (n=15, 13)6.1 ± 2.745.7 ± 2.56
Day 8: 48 hours post-dose (n=15, 14)6.1 ± 2.315.8 ± 2.81
Statistical analysis
  • Pregabalin vs Placebo · ANOVA · p = 0.6797 · Mean difference (final values): 0.20 · 95% CI -0.83 to 1.22
  • Pregabalin vs Placebo · ANOVA · p = 0.4811 · Mean difference (final values): -0.38 · 95% CI -1.54 to 0.77
  • Pregabalin vs Placebo · ANOVA · p = 0.1693 · Mean difference (final values): -0.67 · 95% CI -1.67 to 0.33
  • Pregabalin vs Placebo · ANOVA · p = 0.4034 · Mean difference (final values): -0.45 · 95% CI -1.78 to 0.87
  • Pregabalin vs Placebo · ANOVA · p = 0.1935 · Mean difference (final values): -0.93 · 95% CI -2.36 to 0.50
  • Pregabalin vs Placebo · ANOVA · p = 0.0694 · Mean difference (final values): -1.36 · 95% CI -2.83 to 0.12
  • Pregabalin vs Placebo · ANOVA · p = 0.0396 · Mean difference (final values): -1.55 · 95% CI -3.02 to -0.08
  • Pregabalin vs Placebo · ANOVA · p = 0.1531 · Mean difference (final values): -0.51 · 95% CI -1.25 to 0.24
  • Pregabalin vs Placebo · ANOVA · p = 0.0951 · Mean difference (final values): -1.25 · 95% CI -2.79 to 0.29
  • Pregabalin vs Placebo · ANOVA · p = 0.0614 · Mean difference (final values): -1.38 · 95% CI -2.84 to 0.09
  • Pregabalin vs Placebo · ANOVA · p = 0.1946 · Mean difference (final values): -0.87 · 95% CI -2.29 to 0.54
  • Pregabalin vs Placebo · ANOVA · p = 0.2843 · Mean difference (final values): -0.68 · 95% CI -2.20 to 0.84
  • Pregabalin vs Placebo · ANOVA · p = 0.2150 · Mean difference (final values): -1.05 · 95% CI -2.75 to 0.65
  • Pregabalin vs Placebo · ANOVA · p = 0.9601 · Mean difference (final values): -0.01 · 95% CI -0.44 to 0.42
  • Pregabalin vs Placebo · ANOVA · p = 0.8670 · Mean difference (final values): 0.05 · 95% CI -0.64 to 0.74
  • Pregabalin vs Placebo · ANOVA · p = 0.9024 · Mean difference (final values): -0.05 · 95% CI -0.94 to 0.84
  • Pregabalin vs Placebo · ANOVA · p = 0.9708 · Mean difference (final values): -0.01 · 95% CI -0.67 to 0.65
  • Pregabalin vs Placebo · ANOVA · p = 0.1078 · Mean difference (final values): -0.71 · 95% CI -1.62 to 0.19
  • Pregabalin vs Placebo · ANOVA · p = 0.4460 · Mean difference (final values): -0.33 · 95% CI -1.28 to 0.61
  • Pregabalin vs Placebo · ANOVA · p = 0.5266 · Mean difference (final values): -0.26 · 95% CI -1.13 to 0.62
  • Pregabalin vs Placebo · ANOVA · p = 0.0290 · Mean difference (final values): -0.69 · 95% CI -1.29 to -0.08
  • Pregabalin vs Placebo · ANOVA · p = 0.1830 · Mean difference (final values): -0.78 · 95% CI -2.01 to 0.45
  • Pregabalin vs Placebo · ANOVA · p = 0.9884 · Mean difference (final values): 0.01 · 95% CI -0.90 to 0.91
  • Pregabalin vs Placebo · ANOVA · p = 0.8082 · Mean difference (final values): -0.09 · 95% CI -0.87 to 0.69
SecondaryDaily Pain Score

Daily Pain Score: Day 1 pain intensity over past 24 hours recorded on waking every morning. 0-10 numeric rating scale (NRS): 0 (no pain) to 10 (worst possible pain).

Time frame:
Predose: Daily from 7 days before Visit 2 (start of Intervention 1) until the morning of Visit 5 (end of Intervention 2)
Reported as:
Mean · scores on scale
Daily Pain Score
scores on scalePregabalinPlacebo
Day 1 (n=15, 13)6.2 ± 1.786.3 ± 2.06
Day 2 (n=15, 14)4.4 ± 2.675.4 ± 2.47
Day 3 (n=15, 14)4.1 ± 2.495.1 ± 2.35
Day 4 (n=15, 14)4.2 ± 2.515.0 ± 2.35
Day 5 (n= 15, 14)4.5 ± 2.675.1 ± 2.37
Day 6 (n=15, 14)3.7 ± 2.604.9 ± 2.30
Day 7 (n=15, 14)4.0 ± 2.704.9 ± 2.54
Day 8 (n=14, 14)4.0 ± 2.355.6 ± 2.47
Statistical analysis
  • Pregabalin vs Placebo · ANOVA · p = 0.2101 · Mean difference (final values): -0.92 · 95% CI -2.39 to 0.55
  • Pregabalin vs Placebo · ANOVA · p = 0.1065 · Mean difference (final values): -1.04 · 95% CI -2.33 to 0.24
  • Pregabalin vs Placebo · ANOVA · p = 0.0697 · Mean difference (final values): -0.53 · 95% CI -1.11 to 0.05
  • Pregabalin vs Placebo · ANOVA · p = 0.4589 · Mean difference (final values): -0.49 · 95% CI -1.83 to 0.85
  • Pregabalin vs Placebo · ANOVA · p = 0.1326 · Mean difference (final values): -1.16 · 95% CI -2.69 to 0.38
  • Pregabalin vs Placebo · ANOVA · p = 0.2820 · Mean difference (final values): -0.78 · 95% CI -2.45 to 0.90
  • Pregabalin vs Placebo · ANOVA · p = 0.0108 · Mean difference (final values): -1.33 · 95% CI -2.21 to -0.44
SecondaryDynamic Allodynia Area

Area of dynamic allodynia was assessed using a brush (SENSElab Brush 05; velocity approximately 20 millimeters per second \[mm/s\]) by stimulating along a pattern of 8 radial spokes. Stimulation was started from the non-painful perimetry. Subjects were asked to report change in sensation from non-painful to painful and the spot was marked onto the skin. The area of dynamic allodynia was determined from these 8 distances by calculating the area of an octagon (in centimeter squared \[cm2\]).

Time frame:
Screening, Days 1 & 8: 0 (pre-dose) & 4 hours post-dose,
Reported as:
Mean · cm2
Dynamic Allodynia Area
cm2PregabalinPlacebo
Day 1: pre-dose (n=14, 14)95.8 ± 108.181.6 ± 111.2
Day 1: 4 hours post-dose (n=15, 13)63.0 ± 78.5450.9 ± 78.64
Day 8: pre-dose (n=12, 14)48.4 ± 92.0768.4 ± 83.53
Day 8: 4 hours post-dose (n=15, 13)50.5 ± 83.7268.0 ± 91.41
Statistical analysis
  • Pregabalin vs Placebo · ANOVA · p = 0.9068 · Mean difference (final values): -2.26 · 95% CI -41.78 to 37.27
  • Pregabalin vs Placebo · ANOVA · p = 0.7807 · Mean difference (final values): 4.52 · 95% CI -30.53 to 39.57
  • Pregabalin vs Placebo · ANOVA · p = 0.2293 · Mean difference (final values): -22.51 · 95% CI -61.79 to 16.78
SecondaryDynamic Allodynia Pain Score

Five strokes (each approx. 6 centimeters \[cm\] long) were applied with a standardized brush (SENSELab Brush 05) across the painful site (and a control site) at a constant velocity (20 millimeters per second \[mm/sec\]). Pain in response to brush stimulation of the allodynic area was recorded using an 11-point numeric rating scale from 0 (no pain) to 10 (worst possible pain). Patients were asked to give a pain rating after each brush stroke. A painful sensation was considered as representing brush allodynia.

Time frame:
Screening, Days 1 & 8: 0 (pre-dose), 0.5, 1, 2, 3, 4, 5, and 6 hours post-dose
Reported as:
Mean · scores on scale
Dynamic Allodynia Pain Score
scores on scalePregabalinPlacebo
Day 1: pre-dose (n=14, 13)2.2 ± 2.992.1 ± 3.33
Day 1: 0.5 hours post-dose (n=10, 8)2.8 ± 3.141.9 ± 3.35
Day 1: 1 hour post-dose (n=10, 8)2.3 ± 2.831.8 ± 3.15
Day 1: 2 hours post-dose (n=10, 8)2.5 ± 3.091.7 ± 2.67
Day 1: 3 hours post-dose (n=10, 8)2.3 ± 2.942.3 ± 2.98
Day 1: 4 hours post-dose (n=15, 13)1.5 ± 2.631.2 ± 2.28
Day 1: 5 hours post-dose (n=10, 8)2.2 ± 2.951.9 ± 2.70
Day 1: 6 hours post-dose (n=10, 8)2.1 ± 2.801.9 ± 2.75
Day 8: pre-dose (n=11, 12)1.9 ± 2.932.0 ± 2.97
Day 8: 0.5 hours post-dose (n=7, 8)1.7 ± 2.741.7 ± 2.66
Day 8: 1 hour post-dose (n=7, 8)1.6 ± 2.661.4 ± 2.58
Day 8: 2 hours post-dose (n=7, 8)1.9 ± 2.931.5 ± 2.43
Day 8: 3 hours post-dose (n=9, 8)1.7 ± 2.451.6 ± 2.51
Day 8: 4 hours post-dose (n=14, 13)1.0 ± 1.990.9 ± 1.99
Day 8: 5 hours post-dose (n=9, 8)1.9 ± 2.831.5 ± 2.40
Day 8: 6 hours post-dose (n=9, 8)1.9 ± 3.051.5 ± 2.57
Statistical analysis
  • Pregabalin vs Placebo · ANOVA · p = 0.3774 · Mean difference (final values): 0.36 · 95% CI -0.54 to 1.27
  • Pregabalin vs Placebo · ANOVA · p = 0.4153 · Mean difference (final values): 0.19 · 95% CI -0.33 to 0.70
  • Pregabalin vs Placebo · ANOVA · p = 0.1470 · Mean difference (final values): 0.48 · 95% CI -0.23 to 1.20
  • Pregabalin vs Placebo · ANOVA · p = 0.1862 · Mean difference (final values): -0.45 · 95% CI -1.18 to 0.29
  • Pregabalin vs Placebo · ANOVA · p = 0.8321 · Mean difference (final values): 0.05 · 95% CI -0.45 to 0.55
  • Pregabalin vs Placebo · ANOVA · p = 0.4251 · Mean difference (final values): 0.23 · 95% CI -0.42 to 0.88
  • Pregabalin vs Placebo · ANOVA · p = 0.6394 · Mean difference (final values): 0.13 · 95% CI -0.53 to 0.80
  • Pregabalin vs Placebo · ANOVA · p = 0.9964 · Mean difference (final values): 0.00 · 95% CI -0.68 to 0.68
  • Pregabalin vs Placebo · ANOVA · p = 0.3638 · Mean difference (final values): 0.32 · 95% CI -0.47 to 1.11
  • Pregabalin vs Placebo · ANOVA · p = 0.1202 · Mean difference (final values): 0.42 · 95% CI -0.15 to 0.99
  • Pregabalin vs Placebo · ANOVA · p = 0.1204 · Mean difference (final values): 0.60 · 95% CI -0.19 to 1.39
  • Pregabalin vs Placebo · ANOVA · p = 0.4213 · Mean difference (final values): 0.25 · 95% CI -0.44 to 0.93
  • Pregabalin vs Placebo · ANOVA · p = 0.6028 · Mean difference (final values): 0.11 · 95% CI -0.34 to 0.56
  • Pregabalin vs Placebo · ANOVA · p = 0.3624 · Mean difference (final values): 0.48 · 95% CI -0.68 to 1.64
  • Pregabalin vs Placebo · ANOVA · p = 0.3163 · Mean difference (final values): 0.48 · 95% CI -0.52 to 1.49
SecondaryPunctate Allodynia Area

Area of punctate allodynia was determined using a von Frey filament (OptiHair2). Stimulation was started from the non-painful perimetry and repeated along a pattern of 8 radial spokes. With a movement along each spoke at steps of 5 millimeters (mm), the subjects reported sensation changes from non-painful to painful and the spot was marked on the skin. The area of punctate allodynia was determined from these 8 distances by calculating the area of an octagon (in square centimeter(s)\[cm2\]).

Time frame:
Screening, Days 1 & 8: 0 (pre-dose) and 4 hours post-dose
Reported as:
Mean · cm2
Punctate Allodynia Area
cm2PregabalinPlacebo
Day 1: pre-dose (n=15, 14)75.6 ± 113.365.1 ± 104.8
Day 1: 4 hours post-dose (n=15, 13)68.7 ± 112.654.1 ± 91.21
Day 8: pre-dose (n=13, 14)53.1 ± 102.245.9 ± 74.32
Day 8: 4 hours post-dose (n=15, 13)70.8 ± 106.346.7 ± 80.73
Statistical analysis
  • Pregabalin vs Placebo · ANOVA · p = 0.5919 · Mean difference (final values): 5.39 · 95% CI -16.26 to 27.04
  • Pregabalin vs Placebo · ANOVA · p = 0.3981 · Mean difference (final values): 12.58 · 95% CI -17.70 to 42.87
  • Pregabalin vs Placebo · ANOVA · p = 0.8314 · Mean difference (final values): 2.64 · 95% CI -24.00 to 29.28
SecondaryMechanical Pain Sensitivity Stimulus-Response Function

Mechanical pain sensitivity stimulus response function was assessed at the control and painful sites using calibrated von Frey monofilaments and the SENSElab brush. Seven different von Frey monofilaments (8 -512 milliNewtons \[mN\], force increases by a factor of two from filament to filament) and the brush were applied in a predetermined pseudo-random order. Pain rating for each stimulus: 11-point numeric rating scale (NRS) ranging from 0 (no pain) to 10 (worst possible pain).

Time frame:
Screening, Days 1 & 8: 0 (pre-dose), & 2, 4, and 6 hours post-dose
Reported as:
Mean · scores on scale
Mechanical Pain Sensitivity Stimulus-Response Function
scores on scalePregabalinPlacebo
Day 1: pre-dose (n=14, 14)0.8 ± 0.780.9 ± 0.73
Day 1: 2 hours post-dose (n=14, 14)0.7 ± 0.580.8 ± 0.65
Day 1: 4 hours post-dose (n=14, 14)0.7 ± 0.640.8 ± 0.65
Day 1: 6 hours post-dose (n=14, 14)0.8 ± 0.610.9 ± 0.68
Day 8: pre-dose (n=13, 14)0.7 ± 0.610.8 ± 0.64
Day 8: 2 hours post-dose (=13, 14)0.7 ± 0.500.8 ± 0.66
Day 8: 4 hours post-dose (n=15, 13)0.7 ± 0.650.7 ± 0.62
Day 8: 6 hours post-dose (n=15, 13)0.8 ± 0.670.7 ± 0.59
Statistical analysis
  • Pregabalin vs Placebo · ANOVA · p = 0.7569 · Mean difference (final values): -0.02 · 95% CI -0.14 to 0.10
  • Pregabalin vs Placebo · ANOVA · p = 0.4814 · Mean difference (final values): -0.07 · 95% CI -0.26 to 0.13
  • Pregabalin vs Placebo · ANOVA · p = 0.6222 · Mean difference (final values): -0.07 · 95% CI -0.37 to 0.23
  • Pregabalin vs Placebo · ANOVA · p = 0.3035 · Mean difference (final values): -0.12 · 95% CI -0.35 to 0.12
  • Pregabalin vs Placebo · ANOVA · p = 0.1881 · Mean difference (final values): -0.17 · 95% CI -0.42 to 0.09
  • Pregabalin vs Placebo · ANOVA · p = 0.3159 · Mean difference (final values): 0.08 · 95% CI -0.09 to 0.24
  • Pregabalin vs Placebo · ANOVA · p = 0.8203 · Mean difference (final values): 0.02 · 95% CI -0.22 to 0.27
SecondaryNeuropathic Pain Symptom Inventory (NPSI)

NPSI: subject rated questionnaire to evaluate 5 dimensions of neuropathic pain (dimensions: burning \[superficial\] spontaneous pain, pressing \[deep\] spontaneous pain, paroxysmal pain, evoked pain, and paresthesia/dyesthesia). Includes 10 descriptors ranging from 0 (no symptoms) to 10 (worst symptoms imaginable) and 2 temporal items assessing duration of spontaneous ongoing and paroxysmal pain. Questionnaire generates a score in each relevant dimension. Total score is calculated as the sum of scores of the 10 descriptors, range: 0-100. Higher score indicates greater intensity of pain.

Time frame:
Prior to morning dosing on Day 1 and prior to discharge on Day 8 for each period.
Reported as:
Median · scores on scale
Neuropathic Pain Symptom Inventory (NPSI)
scores on scalePregabalinPlacebo
Category 1 Day 1 (n=15, 14)6.0 (3.0 to 7.0)6.0 (0.0 to 7.0)
Category 1: Day 8 (n=12, 11)5.5 (1.5 to 7.0)6.0 (0.0 to 7.0)
Category 2: Day 1 (n=15, 14)3.0 (1.0 to 5.0)2.5 (1.0 to 4.0)
Category 2: Day 8 (n=12, 11)2.5 (1.5 to 3.3)3.0 (2.0 to 4.5)
Category 3: Day 1 (n=15, 14)1.5 (0.0 to 5.0)3.3 (1.0 to 5.0)
Category 3: Day 8 (n=12, 11)1.8 (0.0 to 3.5)2.0 (0.0 to 5.0)
Category 4: Day 1 (n=15, 14)1.7 (0.0 to 6.0)0.3 (0.0 to 3.3)
Category 4: Day 8 (n=12, 11)2.7 (0.8 to 4.7)0.0 (0.0 to 4.0)
Category 5: Day 1 (n=15, 14)5.0 (0.0 to 7.0)5.0 (1.5 to 7.0)
Category 5: Day 8 (n=12, 11)3.5 (1.5 to 5.5)5.0 (2.0 to 6.0)
Total: Day 1 (n=15, 14)32 (14.0 to 48.0)27 (21.0 to 42.0)
Total: Day 8 (n=12, 11)22 (18.5 to 51.5)24 (20.0 to 46.0)
SecondaryPharmacokinetic Evaluations of Pregabalin

Pharmacokinetic (PK) results are not presented in this report due to early termination of the trial. Pregabalin PK was not measured as there was incomplete data to conduct pharmacokinetic/pharmacodynamic analyses.

Time frame:
Day 1: 0 (pre-dose), 0.5, 1, 2, and 6 hours post-dose; Day 8: 0 (pre-dose), 1, 4, & 6 hours post-dose

Results for this outcome have not been posted.

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Pregabalin—0/15 (0%)12/15 (80%)
Placebo—1/14 (7.1%)9/14 (64.3%)
Most frequent serious events
Most frequent serious events
EventPregabalinPlacebo
Urinary tract infectionInfections and infestations0/151/14
Most frequent other events
Showing 10 of 36
Most frequent other events
EventPregabalinPlacebo
SomnolenceNervous system disorders5/152/14
Urinary tract infectionInfections and infestations4/152/14
DizzinessNervous system disorders4/151/14
HeadacheNervous system disorders3/152/14
Dry mouthGastrointestinal disorders2/151/14
Feeling drunkGeneral disorders2/150/14
PyrexiaGeneral disorders2/150/14
NeuralgiaNervous system disorders2/151/14
Dermoid cystCongenital, familial and genetic disorders1/151/14
Eye painEye disorders0/151/14

Baseline characteristics

Age, Customized
Age, Customized(participants)All Subjects
18-44 years5
45-64 years7
>= 65 years3
Sex/Gender, Customized
Sex/Gender, Customized(gender)All Subjects
Female2
Male13
08

Study locations

4 sites
  • Pfizer Investigational Site
    Randwick, New South Wales 2031, Australia
  • Pfizer Investigational Site
    St Leonards, New South Wales 2065, Australia
  • Pfizer Investigational Site
    Warrawong, New South Wales 2502, Australia
  • Pfizer Investigational Site
    Heidelberg, Victoria 3084, Australia
09

References and documents

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2007, a primary completion of Oct 2008 and a completion of Oct 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Nov 2009, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 15, 2009
First posted
Sep 16, 2009
Start
Feb 2007
Primary completionActual
Oct 2008
CompletionActual
Oct 2008
Results first posted
Nov 9, 2009
Last update
Jan 25, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 25, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00978341
Responsible party
Sponsor
First posted
Sep 16, 2009
Start date
Feb 2007
Primary completion
Oct 2008
Completion
Oct 2008
Results posted
Nov 9, 2009
Last update
Jan 25, 2021

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jan 2010. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pregabalin

Start the discussion